Outcomes of Anastrozole, Letrozole, and Exemestane in Patients With Postmenopausal Breast Cancer
The findings of this comparative effectiveness study using a target trial emulation framework suggest that adjuvant endocrine therapy with exemestane may result in slightly lower DFS and OS compared with anastrozole and letrozole in patients with postmenopausal HR-positive early-stage breast cancer. The findings favor anastrozole or letrozole as initial treatment and highlight the need for future studies to inform AI selection.
Authors
- Kerollos Nashat Wanis (ORCID: https://orcid.org/0000-0003-1934-3380)
- Floriane Jochum (ORCID: https://orcid.org/0000-0001-5009-3936)
- Paul Gougis (ORCID: https://orcid.org/0000-0003-3064-7043)
- Sophie Houzard (ORCID: https://orcid.org/0000-0002-0820-5743)
- Élise Dumas (ORCID: https://orcid.org/0000-0002-7877-719X)
- Enora Laas (ORCID: https://orcid.org/0000-0003-3875-4011)
- Christine Le Bihan-Benjamin (ORCID: https://orcid.org/0000-0002-1868-9358)
- Mats Julius Stensrud (ORCID: https://orcid.org/0000-0001-9641-1936)
- Anne-Sophie Hamy
- Thomas Gaillard
- Fabien Reyal
- Florence Coussy
- Sylvie Giacchetti
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Immunité et Cancer (FR)
- Pitié-Salpêtrière Hospital (FR)
- Hôpital Saint-Louis (FR)
- Institut National du Cancer (FR)
- Institut Jean Godinot (FR)
- École Polytechnique Fédérale de Lausanne (CH)
- Université de Strasbourg (FR)
- Institut Curie (FR)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.50842
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00